ReviewReviews in endocrine & metabolic disorders2024
New insights on diagnosis and treatment of AVP deficiency.
Review in Reviews in endocrine & metabolic disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- Hypophysitis in COVID-19: a systematic review.Pituitary · 2024Pooled it
- The Time of the Hypertonic Saline Infusion Test for the Diagnosis of AVP Deficiency Can Be Shortened With LC-MS/MS.The Journal of clinical endocrinology and metabolism · 2026Trial
- Late recovery from chronic arginine vasopressin deficiency: a multicenter retrospective case-control study.Journal of the Endocrine Society · 2026Article
- Copeptin in acute ischemic stroke: a surrogate marker of AVP-system activation with temporal dynamics and clinical implications.Journal of thrombosis and thrombolysis · 2026Review
- Fracture risks in patients with arginine vasopressin deficiency: a nationwide matched cohort study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
- Challenges and unmet needs in diagnosing polyuria-polydipsia syndrome: National survey by the Italian Society of Endocrinology.Journal of endocrinological investigation · 2026Article
- CANDID Study: Clinical and Molecular Characterization of Congenital Arginine Vasopressin-Resistance and the Use of a Novel Diagnostic Biomarker in Indian Children.Indian journal of pediatrics · 2026Article
- Revisiting the complex interactions in nocturnal polyuria: insights on OSA, ADH and ANP.Nature reviews. Urology · 2025Article
- Arginine vasopressin and copeptin: comparative review and perspective in veterinary medicine.Frontiers in veterinary science · 2025Review
- The endocrine spectrum of Rathke cleft cysts.Frontiers in endocrinology · 2025Review
- Incidence and Treatment of Arginine Vasopressin Deficiency (Central Diabetes Insipidus) in the Setting of Brain Death and Associations with Renal Function and Hemodynamics in Organ Donors.Journal of clinical medicine · 2024Article
- BMP10 Knockdown Modulates Endothelial Cell Immunoreactivity by Inhibiting the HIF-1α Pathway in the Sepsis-Induced Myocardial Injury.Journal of cellular and molecular medicine · 2024Article
- Lesson for the clinical nephrologist: diagnostic approach to polyuria-polydipsia syndrome in the adult.Journal of nephrology · 2024Article
- Transient Arginine Vasopressin Deficiency Induced by Valproic Acid Intoxication: A Case Report.Cureus · 2024Article
- Morbidities and mortality among hospitalized patients with hypopituitarism: Prevalence, causes and management.Reviews in endocrine & metabolic disorders · 2024Review
- Plasma Arginine Vasopressin and Serum Copeptin Concentrations at Rest and After Osmotic- and Non-Osmotic-Based Stimulation Tests in Dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arginine vasopressin deficiency (AVP-D) is one of the main entities of the polyuria-polydipsia syndrome. Its correct diagnosis and differentiation from the other two causes - AVP resistance and primary polydipsia - is crucial as this determines the further management of these patients.Over the last years, several new diagnostic tests using copeptin, the stable surrogate marker of AVP, have been introduced. Among them, hypertonic saline stimulated copeptin was confirmed to reliably and safely improve the diagnostic accuracy to diagnose AVP-D. Due to its simplicity, arginine stimulated copeptin was put forward as alternative test procedure. Glucagon-stimulated copeptin also showed promising results, while the oral growth hormone secretagogue Macimorelin failed to provide a sufficient stimulus. Interestingly, an approach using machine learning techniques also showed promising results concerning diagnostic accuracy.Once AVP-D is diagnosed, further workup is needed to evaluate its etiology. This will partly define the further treatment and management. In general, treatment of AVP-D focuses on desmopressin substitution, with oral formulations currently showing the best tolerance and safety profile. However, in addition to desmopressin substitution, recent data also showed that psychopathological factors play an important role in managing AVP-D patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.